Curative Biosciences

Curative Biosciences FCF Yield

The Free Cash Flow Yield of Curative Biosciences (CBDX) as of Oct 30, 2026 is -49.62 %. In the previous year, Free Cash Flow Yield was -112.46 % — a change of -55.88% (higher).

FCF Yield

-49.62 %

YoY

-55.88%

Last updated:

Free Cash Flow Yield of Curative Biosciences is 2017 -49.62 % . Free Cash Flow Yield of Curative Biosciences was 2016 -112.46 % . It decreases by -55.88% higher compared to the previous year.

The Curative Biosciences FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2014
-559.45 USD
Jan 1, 2015
-253.40 USD
Jan 1, 2016
-112.46 USD
Jan 1, 2017
-49.62 USD
The Curative Biosciences FCF Yield history
YEARFCF YieldYoY
-49.62 %-55.88%
-112.46 %-55.62%
-253.40 %-54.71%
-559.45 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Curative Biosciences Stock analysis

What does Curative Biosciences do? Curative Biosciences Inc is a biotechnology company specializing in the development of innovative therapies for serious diseases. The company was founded in 2011 by a group of experienced scientists, medical experts, and entrepreneurs and is based in San Francisco, California. History Curative Biosciences Inc aims to develop groundbreaking therapies for diseases that currently have no effective treatment options. The company has had an impressive track record in recent years, as evidenced by numerous awards and recognition from reputable institutions and media. Business Model Curative Biosciences Inc has developed a unique business model based on the combination of basic research, product development, and marketing. The company conducts intensive research to identify and develop promising drug candidates. Divisions Curative Biosciences Inc has focused on several divisions to offer a wide range of innovative therapy options: - Oncology: Curative Biosciences Inc has developed a portfolio of drug candidates that specifically target malignant tumors without damaging healthy tissue. - Autoimmune diseases: The company has also developed some promising drug candidates for autoimmune diseases that regulate the immune system and reduce the risk of side effects and complications. - Neurodegenerative diseases: Curative Biosciences Inc is intensively working on the development of therapies against neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS. Products The company has already developed several promising products that are currently in clinical trials. Here are some examples: - CB-01: A drug candidate specifically developed to target aggressive tumors such as lung cancer, pancreatic cancer, and leukemia. - CB-02: A drug candidate that regulates the immune system and could be used in the treatment of autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. - CB-03: A promising drug candidate against Alzheimer's disease that reduces β-amyloid proteins in the brain and could slow down the progression of the disease. Summary Curative Biosciences Inc is an emerging biotechnology company specializing in the development of innovative therapies for serious diseases. The company conducts intensive research and has already developed several promising drug candidates that are currently in clinical trials. Curative Biosciences Inc has developed a unique business model based on the combination of basic research, product development, and marketing. Curative Biosciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Curative Biosciences stock

Free Cash Flow Yield of Curative Biosciences is -49.62 % in 2017.

Free Cash Flow Yield of Curative Biosciences changed from -112.46 % to -49.62 %, representing a -55.88% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Curative Biosciences since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Curative Biosciences with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Curative Biosciences

All Key Metrics — Curative Biosciences